Article: Nateglinide

Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
CAS number 105816-04-4
ATC code A10BX03
PubChem 60026
DrugBank APRD00593
Chemical data
Formula C19H27NO3
Mol. weight 317.423 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 98%
Metabolism  ?
Half life 1.5 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Nateglinide (Starlix®) is a drug for the treatment of type II diabetes.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs and is sold by Novartis.


Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.


Nateglinide is delivered in tablet form.